Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis - PubMed (original) (raw)
Comparative Study
. 1987 Aug;21(3-4):241-3.
doi: 10.1007/BF01966478.
Affiliations
- PMID: 3500589
- DOI: 10.1007/BF01966478
Comparative Study
Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis
R D Pasternak et al. Agents Actions. 1987 Aug.
Abstract
HWA 486 was investigated for its ability to modify the development of adjuvant-induced polyarthritis in Lewis rats. HWA 486 (20 mg/kg/day p.o.), dosed for 8 or 16 days beginning with the day of adjuvant administration, significantly reduced edema, fibrinogen levels, and erythrocyte sedimentation rates (ESR) 42 days later. When HWA 486 (20 mg/kg/day, p.o.) and cyclosporin A (CsA 15 mg/kg/day, p.o.) were tested in the 8-day treatment regimen, the antiarthritic effects of HWA 486 were more sustained. Both compounds reduced the delayed hypersensitivity (DTH) response on day 9 followed by a rebound to an enhanced DTH response on day 21. The PHA-induced mitogenic response of splenocytes from arthritic rats was suppressed on day 9. Treatment with HWA 486 but not CsA restored the splenocyte response to the level of the negative controls.
Similar articles
- Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis.
Hambleton P, McMahon S. Hambleton P, et al. Agents Actions. 1990 Mar;29(3-4):328-32. doi: 10.1007/BF01966465. Agents Actions. 1990. PMID: 2339672 - Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats.
Thoenes GH, Sitter T, Langer KH, Bartlett RR, Schleyerbach R. Thoenes GH, et al. Int J Immunopharmacol. 1989;11(8):921-9. doi: 10.1016/0192-0561(89)90114-8. Int J Immunopharmacol. 1989. PMID: 2613396 - Immunomodulating effects of T-44 in comparison to HWA 486.
Schmidt K, Bekemeier H, Giessler J, Pilopp H. Schmidt K, et al. Agents Actions. 1991 Jan;32(1-2):114-6. doi: 10.1007/BF01983333. Agents Actions. 1991. PMID: 2058457 No abstract available.
Cited by
- Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Breedveld FC, Dayer JM. Breedveld FC, et al. Ann Rheum Dis. 2000 Nov;59(11):841-9. doi: 10.1136/ard.59.11.841. Ann Rheum Dis. 2000. PMID: 11053058 Free PMC article. Review. - Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A.
Thoss K, Henzgen S, Petrow PK, Katenkamp D, Brauer R. Thoss K, et al. Inflamm Res. 1996 Feb;45(2):103-7. doi: 10.1007/BF02265123. Inflamm Res. 1996. PMID: 8907592 - Effects of leflunomide on immune responses and models of inflammation.
Bartlett RR, Anagnostopulos H, Zielinski T, Mattar T, Schleyerbach R. Bartlett RR, et al. Springer Semin Immunopathol. 1993;14(4):381-94. doi: 10.1007/BF00192310. Springer Semin Immunopathol. 1993. PMID: 8322168 Review. No abstract available. - Leflunomide therapy following penetrating keratoplasty in the rat.
Coupland SE, Klebe S, Karow AC, Krause L, Kruse H, Bartlett RR, Hoffmann F. Coupland SE, et al. Graefes Arch Clin Exp Ophthalmol. 1994 Oct;232(10):622-7. doi: 10.1007/BF00193123. Graefes Arch Clin Exp Ophthalmol. 1994. PMID: 8001831 - Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis.
Hambleton P, McMahon S. Hambleton P, et al. Agents Actions. 1990 Mar;29(3-4):328-32. doi: 10.1007/BF01966465. Agents Actions. 1990. PMID: 2339672
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous